Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial
Publication
, Conference
Thompson, AJ; Shiffman, ML; Rossaro, L; Ghalib, R; Han, S-HB; Beavers, KL; Pianko, S; George, J; He, L; Wu, X; Flores, N; Pang, PS; Rossi, SJ ...
Published in: HEPATOLOGY
October 1, 2012
Duke Scholars
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2012
Volume
56
Start / End Page
556A / 557A
Location
Boston, MA
Publisher
WILEY-BLACKWELL
Conference Name
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Thompson, A. J., Shiffman, M. L., Rossaro, L., Ghalib, R., Han, S.-H., Beavers, K. L., … Muir, A. J. (2012). Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial. In HEPATOLOGY (Vol. 56, pp. 556A-557A). Boston, MA: WILEY-BLACKWELL.
Thompson, Alexander J., Mitchell L. Shiffman, Lorenzo Rossaro, Reem Ghalib, Steven-Huy B. Han, Kimberly L. Beavers, Stephen Pianko, et al. “Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial.” In HEPATOLOGY, 56:556A-557A. WILEY-BLACKWELL, 2012.
Thompson AJ, Shiffman ML, Rossaro L, Ghalib R, Han S-HB, Beavers KL, et al. Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial. In: HEPATOLOGY. WILEY-BLACKWELL; 2012. p. 556A-557A.
Thompson, Alexander J., et al. “Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial.” HEPATOLOGY, vol. 56, WILEY-BLACKWELL, 2012, pp. 556A-557A.
Thompson AJ, Shiffman ML, Rossaro L, Ghalib R, Han S-HB, Beavers KL, Pianko S, George J, He L, Wu X, Flores N, Pang PS, Rossi SJ, McHutchison JG, Lee SS, Muir AJ. Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial. HEPATOLOGY. WILEY-BLACKWELL; 2012. p. 556A-557A.
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2012
Volume
56
Start / End Page
556A / 557A
Location
Boston, MA
Publisher
WILEY-BLACKWELL
Conference Name
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics